Echocardiographic and Arterial Pressure Waveform Changes After Reducing Heart Rate With Esmolol in Septic Shock Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02188888 |
Recruitment Status :
Completed
First Posted : July 14, 2014
Last Update Posted : August 7, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Tachycardia Septic Shock | Drug: esmolol |
Study Type : | Observational |
Actual Enrollment : | 45 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Heart Rate Reduction With Esmolol is Associated With Improved Arterial Elastance in Patients With Septic Shock. A Prospective Observational Study |
Study Start Date : | December 2013 |
Actual Primary Completion Date : | June 2014 |
Actual Study Completion Date : | June 2014 |
Group/Cohort | Intervention/treatment |
---|---|
Tachycardic patients
Patients will receive a continuous esmolol infusion to maintain heart rate between 94 and 80 bpm. Norepinephrine will be titrated to achieve a MAP between 65 and 75 mmHg.
|
Drug: esmolol
Strict heart rate control: esmolol at any dose to maintain heart rate between 95 and 80 bpm |
- heart rate [ Time Frame: over a period of four hours ]
- echocardiography [ Time Frame: over a period of four hours ]LV ejection fraction (LVEF) and tricuspidal annular plane solid excursion (TAPSE)
- static arterial elastance [ Time Frame: over a period of four hours ]
- arterial pressure waveform [ Time Frame: over a period of four hours ]systolic, diastolic and dicrotic pressures

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- septic shock criteria
- presence of heart rate > 95 bpm.
Exclusion Criteria:
- Pregnancy
- age < 18

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02188888
Italy | |
Department of Anesthesiology and Intensive care of the University of Rome La Sapienza | |
Rome, Italy, 00161 |
Principal Investigator: | Andrea Morelli, MD | University of Roma La Sapienza |
Responsible Party: | Andrea Morelli, associate professor, University of Roma La Sapienza |
ClinicalTrials.gov Identifier: | NCT02188888 |
Other Study ID Numbers: |
2309 |
First Posted: | July 14, 2014 Key Record Dates |
Last Update Posted: | August 7, 2015 |
Last Verified: | August 2015 |
septic shock esmolol tachycardia betablockers |
Shock, Septic Tachycardia Shock Pathologic Processes Sepsis Infection Systemic Inflammatory Response Syndrome Inflammation Arrhythmias, Cardiac Heart Diseases |
Cardiovascular Diseases Cardiac Conduction System Disease Esmolol Adrenergic beta-1 Receptor Antagonists Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs |